Анализ противоопухолевого эффекта эндостатина в отношении плоскоклеточного рака полости рта по результатам экспериментальных исследований
Ключевые слова:
эндостатин, плоскоклеточный рак полости рта, неоангиогенез, метастазирование
Аннотация
При плоскоклеточном раке полости рта основной причиной летальных исходов является метастазирование в регионарные лимфатические узлы. Злокачественный рост и формирование метастазов напрямую зависят от степени кровоснабжения первичного очага новообразования. Известно, что по мере прогрессирования опухолевый процесс сопровождается нарушением сбалансированной в норме системы регуляции ангиогенеза с превалированием уровня ангиогенных стимуляторов над ингибиторами. В связи с этим, использование антиангиогенных средств является патофизиологически обоснованным методом борьбы со злокачественным ростом. В обзоре обсуждаются данные доклинических исследований участия эндостатина, природного ингибитора ангиогенеза, в процессах подавления прогрессии и метастазирования плоскоклеточного рака челюстно-лицевой области. Проанализированы патогенетические механизмы ингибирования эндостатином опухолевого роста в экспериментальных моделях рака полости рта. Эндостатин можно рассматривать в качестве потенциального противоопухолевого средства для лечения данной нозологии.
Скачивания
Данные скачивания пока недоступны.
Литература
1. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИРЦ радиологии» Минздрава России; 2018. 250 с.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1): 7-30. doi: 10.3322/caac.21332.
3. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet. 2008; 371(9625): 1695-709. doi: 10.1016/S0140-6736(08)60728-X.
4. Pezzuto F., Buonaguro L., Caponigro F., Ionna F., Starita N., Annunziata C. et al. Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies. Oncology. 2015; 89(3): 125-36. doi: 10.1159/000381717.
5. Marur S., Forastiere A.A. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016; 91(3): 386-96. doi: 10.1016/j.mayocp.2015.12.017.
6. Ferris R.L., Xi L., Seethala R.R., Chan J., Desai S., Hoch B., Gooding W. et al. Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer. Clin Cancer Res. 2011; 17(7): 1858-66. doi: 10.1158/1078-0432.CCR-10-3110.
7. Blasco MA, Svider PF, Raza SN, Jacobs JR, Folbe AJ, Saraf P, Eloy JA, Baredes S, Fribley AM. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. Laryngoscope. 2017; 127(11): 2565-9. doi: 10.1002/lary.26629.
8. Xing Y., Zhang J., Lin H., Gold K.A., Sturgis E.M., Garden A.S. et al. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. 2016; 122(4): 534-45. doi: 10.1002/cncr.29780.
9. Murakami R., Nakayama H., Semba A., Hiraki A., Nagata M., Kawahara K. et al. Prognostic impact of the level of nodal involvement: Retrospective analysis of patients with advanced oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2017; 55(1): 50-5. doi: 10.1016/j.bjoms.2016.08.026.
10. Chen C.C., Lin J.C., Chen K.W. Lymph node ratio as a prognostic factor in head and neck cancer patients. Radiat Oncol. 2015; 10: 181. doi: 10.1186/s13014-015-0490-9.
11. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(6 Suppl 16): 15-8. doi: 10.1053/sonc.2002.37263.
12. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985; 43: 175-203.
13. Folkman J., Kalluri R. Cancer without disease. Nature. 2004; 427(6977): 787. doi: 10.1038/427787a.
14. Jayson G.C., Kerbel R., Ellis L.M., Harris A.L. Antiangiogenic therapy in oncology: current status and future directions. The Lancet. 2016; 388(10043): 518-29. doi: 10.1016/S0140-6736(15)01088-0.
15. Kyzas P.A., Stefanou D., Batistatou A., Agnantis N.J. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005; 131(9): 624-630. doi: 10.1007/s00432-005-0003-6.
16. Seki S., Fujiwara M., Matsuura M., Fujita S., Ikeda H., Asahina I. et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol. 2011; 47(7): 588-93. doi: 10.1016/j.oraloncology.2011.04.013.
17. de Oliveira M.V.M., Gomes É.P.P., Pereira C.S., de Souza L.R., Barros L.O., Mendes D.C. et al. Prognostic value of microvessel density and p53 expression on the locoregional metastasis and survival of the patients with head and neck squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2013; 21(5): 444-51. doi: 10.1097/PAI.0b013e3182773125.
18. Yamamoto C., Yuasa K., Okamura K., Shiraishi T., Miwa K. Vascularity as assessed by Doppler intraoral ultrasound around the invasion front of tongue cancer is a predictor of pathological grade of malignancy and cervical lymph node metastasis. Dentomaxillofac Radiol. 2016; 45(3): 20150372. doi: 10.1259/dmfr.20150372.
19. Yadav L., Puri N., Rastogi V., Satpute P., Sharma V. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res. 2015; 9(6): XE01- XE05. doi: 10.7860/JCDR/2015/12016.6135.
20. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006; 312(5): 594-607. doi: 10.1016/j.yexcr.2005.11.015.
21. Huang X., Wong M.K., Zhao Q., Zhu Z., Wang K.Z., Huang N. et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res. 2001; 61(2): 478-81.
22. Jin X., Bookstein R., Wills K., Avanzini J., Tsai V., LaFace D. et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 2001; 8(12): 982-9. doi: 10.1038/sj.cgt.7700396.
23. Abdollahi A., Hahnfeldt P., Maercker C., Gröne H.J., Debus J., Ansorge W. et al. Endostatin's antiangiogenic signaling network. Mol Cell. 2004; 13(5): 649-63.
24. Cui R., Ohashi R., Takahashi F., Yoshioka M., Tominaga S., Sasaki S. et. Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro. Cancer Sci. 2007; 98(6): 830-7. doi: 10.1111/j.1349-7006.2007.00459.x.
25. Yokoyama Y., Ramakrishnan S. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer. 2007; 121(11): 2402-9. doi: 10.1002/ijc.22935.
26. Dkhissi F., Lu H., Soria C., Opolon P., Griscelli F., Liu H. et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther. 2003; 14(10): 997-1008. doi: 10.1089/104303403766682250.
27. Jia Y., Liu M., Huang W., Wang Z., He Y., Wu J. et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res. 2012; 18(2): 315-23. doi: 10.1007/s12253-011-9447-y.
28. Lee J.H., Isayeva T., Larson M.R., Sawant A., Cha H.R., Chanda D. et al. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Proc Natl Acad Sci USA. 2015; 112(5): 1392-7. doi: 10.1073/pnas.1417660112.
29. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M. et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999; 274(17): 11721-6.
30. Hanai J., Dhanabal M., Karumanchi S.A., Albanese C., Waterman M., Chan B. et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002; 277(19): 16464-9. doi: 10.1074/jbc.M112274200.
31. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C.R. et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA. 2001; 98(3): 1024-9. doi: 10.1073/pnas.031564998.
32. Wickström S.A., Alitalo K., Keski-Oja J. Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002; 62(19): 5580-9.
33. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA. 2003; 100(8): 4766-71. doi: 10.1073/pnas.0730882100.
34. Peng F., Xu Z., Wang J., Chen Y., Li Q., Zuo Y. et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PloS one. 2012; 7(4): e34646. doi: 10.1371/journal.pone.0034646.
35. Denaro, N., Russi E.G., Colantonio, I., Adamo, V., Merlano, M.C. The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology. 2012; 83(2): 108-16. doi: 10.1159/000339542.
36. Walia A., Yang J.F., Huang Y.H., Rosenblatt M.I., Chang J.H., Azar D.T. Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 2015; 1850(12): 2422-38. doi: 10.1016/j.bbagen.2015.09.007.
37. Jung S., Sielker S., Purcz N., Sproll C., Acil Y., Kleinheinz J. Analysis of angiogenic markers in oral squamous cell carcinoma-gene and protein expression. Head Face Med. 2015; 11: 19. doi: 10.1186/s13005-015-0076-7.
38. Szafarowski T., Sierdzinski J., Szczepanski M.J., Whiteside T.L., Ludwig N., Krzeski A. Microvessel density in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2018; 275(7): 1845-51. doi: 10.1007/s00405-018-4996-2.
39. Mardani M., Tadbir A.A., Ranjbar M.A., Khademi B., Fattahi M.J., Rahbar A. Serum Endostatin Levels in Oral Squamous Cell Carcinoma. Iran J Otorhinolaryngol. 2018; 30(98): 125-30.
40. Nikitakis N.G., Rivera H., Lopes M.A., Siavash H., Reynolds M.A., Ord R.A. at al. Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am J Clin Pathol. 2003; 119(4): 574-86. doi: 10.1309/JD3D-HGCD-GAUN-1R0J.
41. Adhim Z., Lin X., Huang W., Morishita N., Nakamura T., Yasui H. et al. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther. 2012; 19(2): 144-52. doi: 10.1038/cgt.2011.79.
42. Wilson R.F., Morse M.A., Pei P., Renner R.J., Schuller D.E., Robertson F.M. et al. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res. 2003; 23(2B): 1289-95.
43. Sarode G.S., Sarode S.C., Patil A., Anand R., Patil S.G., Rao R.S. et al. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract. 2015; 16(7): 595-602.
44. Nyberg P., Heikkilä P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H. et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and-13. J Biol Chem. 2003; 278(25): 22404-11. doi: 10.1074/jbc.M210325200.
45. Кондакова И.В., Клишо Е.В., Савенкова О.В., Шишкин Д.А., Чойнзонов Е.Л. Патогенетическая значимость системы матриксных металлопротеиназ при плоскоклеточном раке головы и шеи. Сибирский онкологический журнал. 2011; 1 (43): 29-33.
46. Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T., Nonaka S. et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004; 10(2): 634-40.
47. Hebert C., Siavash H., Norris K., Nikitakis N.G., Sauk J.J. Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells. Int J Cancer. 2005. 114(2): 195-201. doi: 10.1002/ijc.20692.
48. Fukumoto S., Morifuji M., Katakura Y., Ohishi M., Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis. 2005; 22(1): 31-8. doi: 10.1007/s10585-005-3973-5.
49. Alahuhta I., Aikio M., Väyrynen O., Nurmenniemi S., Suojanen J., Teppo S. et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment. Exp Cell Res. 2015; 336(1): 130-40. doi: 10.1016/j.yexcr.2015.06.012.
2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1): 7-30. doi: 10.3322/caac.21332.
3. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet. 2008; 371(9625): 1695-709. doi: 10.1016/S0140-6736(08)60728-X.
4. Pezzuto F., Buonaguro L., Caponigro F., Ionna F., Starita N., Annunziata C. et al. Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies. Oncology. 2015; 89(3): 125-36. doi: 10.1159/000381717.
5. Marur S., Forastiere A.A. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016; 91(3): 386-96. doi: 10.1016/j.mayocp.2015.12.017.
6. Ferris R.L., Xi L., Seethala R.R., Chan J., Desai S., Hoch B., Gooding W. et al. Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer. Clin Cancer Res. 2011; 17(7): 1858-66. doi: 10.1158/1078-0432.CCR-10-3110.
7. Blasco MA, Svider PF, Raza SN, Jacobs JR, Folbe AJ, Saraf P, Eloy JA, Baredes S, Fribley AM. Systemic therapy for head and neck squamous cell carcinoma: Historical perspectives and recent breakthroughs. Laryngoscope. 2017; 127(11): 2565-9. doi: 10.1002/lary.26629.
8. Xing Y., Zhang J., Lin H., Gold K.A., Sturgis E.M., Garden A.S. et al. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. 2016; 122(4): 534-45. doi: 10.1002/cncr.29780.
9. Murakami R., Nakayama H., Semba A., Hiraki A., Nagata M., Kawahara K. et al. Prognostic impact of the level of nodal involvement: Retrospective analysis of patients with advanced oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2017; 55(1): 50-5. doi: 10.1016/j.bjoms.2016.08.026.
10. Chen C.C., Lin J.C., Chen K.W. Lymph node ratio as a prognostic factor in head and neck cancer patients. Radiat Oncol. 2015; 10: 181. doi: 10.1186/s13014-015-0490-9.
11. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(6 Suppl 16): 15-8. doi: 10.1053/sonc.2002.37263.
12. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985; 43: 175-203.
13. Folkman J., Kalluri R. Cancer without disease. Nature. 2004; 427(6977): 787. doi: 10.1038/427787a.
14. Jayson G.C., Kerbel R., Ellis L.M., Harris A.L. Antiangiogenic therapy in oncology: current status and future directions. The Lancet. 2016; 388(10043): 518-29. doi: 10.1016/S0140-6736(15)01088-0.
15. Kyzas P.A., Stefanou D., Batistatou A., Agnantis N.J. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005; 131(9): 624-630. doi: 10.1007/s00432-005-0003-6.
16. Seki S., Fujiwara M., Matsuura M., Fujita S., Ikeda H., Asahina I. et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors. Oral Oncol. 2011; 47(7): 588-93. doi: 10.1016/j.oraloncology.2011.04.013.
17. de Oliveira M.V.M., Gomes É.P.P., Pereira C.S., de Souza L.R., Barros L.O., Mendes D.C. et al. Prognostic value of microvessel density and p53 expression on the locoregional metastasis and survival of the patients with head and neck squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2013; 21(5): 444-51. doi: 10.1097/PAI.0b013e3182773125.
18. Yamamoto C., Yuasa K., Okamura K., Shiraishi T., Miwa K. Vascularity as assessed by Doppler intraoral ultrasound around the invasion front of tongue cancer is a predictor of pathological grade of malignancy and cervical lymph node metastasis. Dentomaxillofac Radiol. 2016; 45(3): 20150372. doi: 10.1259/dmfr.20150372.
19. Yadav L., Puri N., Rastogi V., Satpute P., Sharma V. Tumour angiogenesis and angiogenic inhibitors: a review. J Clin Diagn Res. 2015; 9(6): XE01- XE05. doi: 10.7860/JCDR/2015/12016.6135.
20. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006; 312(5): 594-607. doi: 10.1016/j.yexcr.2005.11.015.
21. Huang X., Wong M.K., Zhao Q., Zhu Z., Wang K.Z., Huang N. et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect. Cancer Res. 2001; 61(2): 478-81.
22. Jin X., Bookstein R., Wills K., Avanzini J., Tsai V., LaFace D. et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 2001; 8(12): 982-9. doi: 10.1038/sj.cgt.7700396.
23. Abdollahi A., Hahnfeldt P., Maercker C., Gröne H.J., Debus J., Ansorge W. et al. Endostatin's antiangiogenic signaling network. Mol Cell. 2004; 13(5): 649-63.
24. Cui R., Ohashi R., Takahashi F., Yoshioka M., Tominaga S., Sasaki S. et. Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro. Cancer Sci. 2007; 98(6): 830-7. doi: 10.1111/j.1349-7006.2007.00459.x.
25. Yokoyama Y., Ramakrishnan S. Binding of endostatin to human ovarian cancer cells inhibits cell attachment. Int J Cancer. 2007; 121(11): 2402-9. doi: 10.1002/ijc.22935.
26. Dkhissi F., Lu H., Soria C., Opolon P., Griscelli F., Liu H. et al. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther. 2003; 14(10): 997-1008. doi: 10.1089/104303403766682250.
27. Jia Y., Liu M., Huang W., Wang Z., He Y., Wu J. et al. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res. 2012; 18(2): 315-23. doi: 10.1007/s12253-011-9447-y.
28. Lee J.H., Isayeva T., Larson M.R., Sawant A., Cha H.R., Chanda D. et al. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Proc Natl Acad Sci USA. 2015; 112(5): 1392-7. doi: 10.1073/pnas.1417660112.
29. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M. et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999; 274(17): 11721-6.
30. Hanai J., Dhanabal M., Karumanchi S.A., Albanese C., Waterman M., Chan B. et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002; 277(19): 16464-9. doi: 10.1074/jbc.M112274200.
31. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C.R. et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA. 2001; 98(3): 1024-9. doi: 10.1073/pnas.031564998.
32. Wickström S.A., Alitalo K., Keski-Oja J. Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002; 62(19): 5580-9.
33. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci USA. 2003; 100(8): 4766-71. doi: 10.1073/pnas.0730882100.
34. Peng F., Xu Z., Wang J., Chen Y., Li Q., Zuo Y. et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PloS one. 2012; 7(4): e34646. doi: 10.1371/journal.pone.0034646.
35. Denaro, N., Russi E.G., Colantonio, I., Adamo, V., Merlano, M.C. The role of antiangiogenic agents in the treatment of head and neck cancer. Oncology. 2012; 83(2): 108-16. doi: 10.1159/000339542.
36. Walia A., Yang J.F., Huang Y.H., Rosenblatt M.I., Chang J.H., Azar D.T. Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 2015; 1850(12): 2422-38. doi: 10.1016/j.bbagen.2015.09.007.
37. Jung S., Sielker S., Purcz N., Sproll C., Acil Y., Kleinheinz J. Analysis of angiogenic markers in oral squamous cell carcinoma-gene and protein expression. Head Face Med. 2015; 11: 19. doi: 10.1186/s13005-015-0076-7.
38. Szafarowski T., Sierdzinski J., Szczepanski M.J., Whiteside T.L., Ludwig N., Krzeski A. Microvessel density in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2018; 275(7): 1845-51. doi: 10.1007/s00405-018-4996-2.
39. Mardani M., Tadbir A.A., Ranjbar M.A., Khademi B., Fattahi M.J., Rahbar A. Serum Endostatin Levels in Oral Squamous Cell Carcinoma. Iran J Otorhinolaryngol. 2018; 30(98): 125-30.
40. Nikitakis N.G., Rivera H., Lopes M.A., Siavash H., Reynolds M.A., Ord R.A. at al. Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes. Am J Clin Pathol. 2003; 119(4): 574-86. doi: 10.1309/JD3D-HGCD-GAUN-1R0J.
41. Adhim Z., Lin X., Huang W., Morishita N., Nakamura T., Yasui H. et al. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther. 2012; 19(2): 144-52. doi: 10.1038/cgt.2011.79.
42. Wilson R.F., Morse M.A., Pei P., Renner R.J., Schuller D.E., Robertson F.M. et al. Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res. 2003; 23(2B): 1289-95.
43. Sarode G.S., Sarode S.C., Patil A., Anand R., Patil S.G., Rao R.S. et al. Inflammation and Oral Cancer: An Update Review on Targeted Therapies. J Contemp Dent Pract. 2015; 16(7): 595-602.
44. Nyberg P., Heikkilä P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H. et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and-13. J Biol Chem. 2003; 278(25): 22404-11. doi: 10.1074/jbc.M210325200.
45. Кондакова И.В., Клишо Е.В., Савенкова О.В., Шишкин Д.А., Чойнзонов Е.Л. Патогенетическая значимость системы матриксных металлопротеиназ при плоскоклеточном раке головы и шеи. Сибирский онкологический журнал. 2011; 1 (43): 29-33.
46. Katayama A., Bandoh N., Kishibe K., Takahara M., Ogino T., Nonaka S. et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004; 10(2): 634-40.
47. Hebert C., Siavash H., Norris K., Nikitakis N.G., Sauk J.J. Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells. Int J Cancer. 2005. 114(2): 195-201. doi: 10.1002/ijc.20692.
48. Fukumoto S., Morifuji M., Katakura Y., Ohishi M., Nakamura S. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis. 2005; 22(1): 31-8. doi: 10.1007/s10585-005-3973-5.
49. Alahuhta I., Aikio M., Väyrynen O., Nurmenniemi S., Suojanen J., Teppo S. et al. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment. Exp Cell Res. 2015; 336(1): 130-40. doi: 10.1016/j.yexcr.2015.06.012.
Опубликован
2020-11-26
Как цитировать
Тугузбаева Г. М., Павлов В. Н., Еникеев Д. А. Анализ противоопухолевого эффекта эндостатина в отношении плоскоклеточного рака полости рта по результатам экспериментальных исследований // Патологическая физиология и экспериментальная терапия. 2020. Т. 64. № 4. С. 134–139.
Выпуск
Раздел
Обзоры
